B+
Bull case
20%
Probability
Target price
$3.20
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
GANX
Gain TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
FDA IND authorization, planned Q3 Phase 2 initiation, and potentially durable biomarker and MDS-UPDRS signals could improve confidence in rexaceract’s disease-modifying thesis [#SEC-8K-2026-08-11].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Early-stage pipeline and clinical execution create high event volatility, with rexaceract representing the main near-term value driver.
Momentum
82
Value
41
Sentiment
55
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.50 · Bull $3.20 · Bear $0.75Analysis 2026-09-05; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-05 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $7.20
Why
Momentum82 · Δ7d -
Value41 · Δ7d -0.0
Sentiment55 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Early-stage pipeline and clinical execution create high event volatility, with rexaceract representing the main near-term value driver.
- • GT-04686 remains preclinical/IND-enabling, so its indication-selection catalyst has limited near-term validation.
- • The thesis remains concentrated in early clinical evidence.
Catalyst clock
2026-12-04
Rexaceract Phase 2 initiation
Lead driver: Sentiment · See AI snapshot
Momentum
82
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
55
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 82.4 / Value 41.2 / Sentiment 55.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-05. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.75
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$89.03M
Beta
0.07
Shares Out
43.64M
P/E (TTM) · Derived
-3.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-4.28
Rev YoY
-100.0%
EPS YoY
-43.1%
Gross Margin
-51.5%
Op Margin
-
Net Debt
-$20.11M
Current Ratio
4.36
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data